Trimel Pharmaceuticals Given New C$2.00 Price Target at RBC Capital (TRL)
Equities researchers at RBC Capital reduced their target price on shares of Trimel Pharmaceuticals (TSE:TRL) from C$2.50 to C$2.00 in a research report issued on Friday, AmericanBankingNews.com reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s target price points to a potential upside of 393.83% from the company’s current price.
Shares of Trimel Pharmaceuticals (TSE:TRL) traded down 46.00% during mid-day trading on Friday, hitting $0.405. The stock had a trading volume of 2,639,553 shares. Trimel Pharmaceuticals has a one year low of $0.51 and a one year high of $2.41. The stock’s 50-day moving average is $0.85 and its 200-day moving average is $0.9.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.